October 12, 2023
Eli Lilly has persuaded the Patent Trial and Appeal Board to invalidate a Teva Pharmaceuticals patent for the migraine drug Ajovy, shortly after a Massachusetts federal judge overturned a related $176.5 million verdict against Eli Lilly.
October 17, 2022
The Patent Trial and Appeal Board has agreed to review the validity of a patent on Teva's migraine treatment drug Ajovy, marking the latest development in Teva's battle with Eli Lilly over its competing drug Emgality.